Ali Tafazzoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Tafazzoli has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- A. Mark Fendrick
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan
9 shared publications - Weicheng Ye
PPD Clinical Research Services, Thermo Fisher Scientific, Waltham, Massachusetts
9 shared publications - Anuraag R. Kansal
Grail, Inc., Menlo Park, USA
8 shared publications - Denise Zou
Surgical oncologist and research Director of Guatemala’s Cancer Institute (INCAN), Guatemala City, MD, Guatemala
7 shared publications - Sana Raoof
Radiation Oncology Brown University Health Brown School of Public Health Providence Rhode Island USA
7 shared publications - Walter Morris
University of Arkansas, Little Rock, AR
7 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 4: Weighted IRRs for Overall HCS Population and Gene Mutation Groupings by Cancer Type
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 4: Weighted IRRs for Overall HCS Population and Gene Mutation Groupings by Cancer Type
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 3: Cancer Risk by Gene Mutations and The Associated Risk of Cancer in The General Population
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 3: Cancer Risk by Gene Mutations and The Associated Risk of Cancer in The General Population
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 5: Sensitivity of MCED by Cancer Type and Stage
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 5: Sensitivity of MCED by Cancer Type and Stage
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 2: Incidence Rate Ratios for Cancer Survivor by Age Group vs. the General Population by Cancer Type
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 2: Incidence Rate Ratios for Cancer Survivor by Age Group vs. the General Population by Cancer Type
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 1: Cancer Survivor Mortality Hazard Ratios
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Supplementary Table 1: Cancer Survivor Mortality Hazard Ratios
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Background:Cancer remains a significant global health challenge, particularly for subpopulations with risk factors including genetic predisposition, comorbidities, and lifestyle, along with age. The Galleri multicancer early detection (MCED) test is projected to be cost-effective for individuals ≥50 years of age. However, its potential value in subpopulations with elevated cancer risk remains underexplored. This study evaluates the cost-effectiveness (CE) of the Galleri test combined with usual care screening in subpopulations with varying cancer risk, including impact on overall cancer burden.Methods:A hybrid cohort-level model evaluated US subpopulations of 50 to 79 years of age with additional risk factors, incorporating updated cancer incidence rates and excess competing mortality. The model estimated lifetime economic and clinical outcomes of annual MCED testing. Analyses focused on individuals with obesity, diabetes, smoking history, heavy alcohol use, genetic predispositions, immunocompromising conditions, family history, and cancer survivors.Results:The Galleri test was cost-effective across all specified subpopulations, with incremental CE ratios (ICER) below the general population benchmark of $66,043 per quality-adjusted life-year. Subpopulations with higher cancer incidence, such as those with hereditary cancer syndromes, showed lower ICERs, underscoring the CE in targeted screening. However, targeted approaches address a smaller fraction of the population burden. These findings depend on translating overall MCED test performance to higher-risk groups. Sensitivity analyses confirmed the robustness of these findings, emphasizing MCED’s potential to reduce late-stage cancer burden.Conclusions:Prioritizing higher-risk groups yields more favorable CE but affects a smaller overall population burden.Impact:This study compares how MCED testing strategies affect CE and population health benefits.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Background:Cancer remains a significant global health challenge, particularly for subpopulations with risk factors including genetic predisposition, comorbidities, and lifestyle, along with age. The Galleri multicancer early detection (MCED) test is projected to be cost-effective for individuals ≥50 years of age. However, its potential value in subpopulations with elevated cancer risk remains underexplored. This study evaluates the cost-effectiveness (CE) of the Galleri test combined with usual care screening in subpopulations with varying cancer risk, including impact on overall cancer burden.Methods:A hybrid cohort-level model evaluated US subpopulations of 50 to 79 years of age with additional risk factors, incorporating updated cancer incidence rates and excess competing mortality. The model estimated lifetime economic and clinical outcomes of annual MCED testing. Analyses focused on individuals with obesity, diabetes, smoking history, heavy alcohol use, genetic predispositions, immunocompromising conditions, family history, and cancer survivors.Results:The Galleri test was cost-effective across all specified subpopulations, with incremental CE ratios (ICER) below the general population benchmark of $66,043 per quality-adjusted life-year. Subpopulations with higher cancer incidence, such as those with hereditary cancer syndromes, showed lower ICERs, underscoring the CE in targeted screening. However, targeted approaches address a smaller fraction of the population burden. These findings depend on translating overall MCED test performance to higher-risk groups. Sensitivity analyses confirmed the robustness of these findings, emphasizing MCED’s potential to reduce late-stage cancer burden.Conclusions:Prioritizing higher-risk groups yields more favorable CE but affects a smaller overall population burden.Impact:This study compares how MCED testing strategies affect CE and population health benefits.
- Open Access
- 27 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2085-2094
Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Background: Cancer remains a significant global health challenge, particularly for subpopulations with risk factors including genetic predisposition, comorbidities, and lifestyle, along with age. The Galleri multicancer early detection (MCED) test is projected to be cost-effective for individuals ≥50 years of age. However, its potential value in subpopulations with elevated cancer risk remains underexplored. This study evaluates the cost-effectiveness (CE) of the Galleri test combined with usual care screening in subpopulations with varying cancer risk, including impact on overall cancer burden. Methods: A hybrid cohort-level model evaluated US subpopulations of 50 to 79 years of age with additional risk factors, incorporating updated cancer incidence rates and excess competing mortality. The model estimated lifetime economic and clinical outcomes of annual MCED testing. Analyses focused on individuals with obesity, diabetes, smoking history, heavy alcohol use, genetic predispositions, immunocompromising conditions, family history, and cancer survivors. Results: The Galleri test was cost-effective across all specified subpopulations, with incremental CE ratios (ICER) below the general population benchmark of $66,043 per quality-adjusted life-year. Subpopulations with higher cancer incidence, such as those with hereditary cancer syndromes, showed lower ICERs, underscoring the CE in targeted screening. However, targeted approaches address a smaller fraction of the population burden. These findings depend on translating overall MCED test performance to higher-risk groups. Sensitivity analyses confirmed the robustness of these findings, emphasizing MCED’s potential to reduce late-stage cancer burden. Conclusions: Prioritizing higher-risk groups yields more favorable CE but affects a smaller overall population burden. Impact: This study compares how MCED testing strategies affect CE and population health benefits.
- 27 August 2025
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 34 (11) , 2085-2094
Open AccessImpact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States
Background: Cancer remains a significant global health challenge, particularly for subpopulations with risk factors including genetic predisposition, comorbidities, and lifestyle, along with age. The Galleri multicancer early detection (MCED) test is projected to be cost-effective for individuals ≥50 years of age. However, its potential value in subpopulations with elevated cancer risk remains underexplored. This study evaluates the cost-effectiveness (CE) of the Galleri test combined with usual care screening in subpopulations with varying cancer risk, including impact on overall cancer burden. Methods: A hybrid cohort-level model evaluated US subpopulations of 50 to 79 years of age with additional risk factors, incorporating updated cancer incidence rates and excess competing mortality. The model estimated lifetime economic and clinical outcomes of annual MCED testing. Analyses focused on individuals with obesity, diabetes, smoking history, heavy alcohol use, genetic predispositions, immunocompromising conditions, family history, and cancer survivors. Results: The Galleri test was cost-effective across all specified subpopulations, with incremental CE ratios (ICER) below the general population benchmark of $66,043 per quality-adjusted life-year. Subpopulations with higher cancer incidence, such as those with hereditary cancer syndromes, showed lower ICERs, underscoring the CE in targeted screening. However, targeted approaches address a smaller fraction of the population burden. These findings depend on translating overall MCED test performance to higher-risk groups. Sensitivity analyses confirmed the robustness of these findings, emphasizing MCED’s potential to reduce late-stage cancer burden. Conclusions: Prioritizing higher-risk groups yields more favorable CE but affects a smaller overall population burden. Impact: This study compares how MCED testing strategies affect CE and population health benefits.
- Open Access
- 20 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e029042
Cost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States
Background: In the EMPEROR‐Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction), empagliflozin plus standard of care reduced the composite of cardiovascular death or hospitalization for heart failure versus standard of care in adults with heart failure with reduced ejection fraction. This analysis investigated the cost‐effectiveness of the 2 regimens from the perspective of US payors. Methods and Results: A Markov cohort model was developed based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score quartiles and death. Transition probabilities between health states, risk of cardiovascular/all‐cause death, hospitalization for heart failure and adverse events, treatment discontinuation, and health utilities were estimated from trial data. Medicare and commercial payment rates were combined for treatment acquisition, acute event management, and disease management. An annual discount rate of 3% was used. Empagliflozin plus standard of care yielded 18% fewer hospitalizations for heart failure and 6% fewer deaths versus standard of care over a lifetime, providing cost‐offsets while adding 0.19 life years and 0.19 quality‐adjusted life years at an incremental cost of $16 815/patient. The incremental cost‐effectiveness ratio was $87 725/quality‐adjusted life years gained. Results were consistent across payors, subpopulations, and in deterministic sensitivity analyses. In probabilistic sensitivity analyses, empagliflozin plus standard of care was cost‐effective in 3%, 62%, and 80% of iterations at thresholds of $50 000, $100 000, and $150 000/quality‐adjusted life years. Conclusions: Empagliflozin plus standard of care may prevent hospitalizations for heart failure, extend life, and increase quality‐adjusted life years for patients with heart failure with reduced ejection fraction at an acceptable cost for US payors.
- 20 February 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (4) , e029042
Open AccessCost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States
Background: In the EMPEROR‐Reduced trial (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction), empagliflozin plus standard of care reduced the composite of cardiovascular death or hospitalization for heart failure versus standard of care in adults with heart failure with reduced ejection fraction. This analysis investigated the cost‐effectiveness of the 2 regimens from the perspective of US payors. Methods and Results: A Markov cohort model was developed based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score quartiles and death. Transition probabilities between health states, risk of cardiovascular/all‐cause death, hospitalization for heart failure and adverse events, treatment discontinuation, and health utilities were estimated from trial data. Medicare and commercial payment rates were combined for treatment acquisition, acute event management, and disease management. An annual discount rate of 3% was used. Empagliflozin plus standard of care yielded 18% fewer hospitalizations for heart failure and 6% fewer deaths versus standard of care over a lifetime, providing cost‐offsets while adding 0.19 life years and 0.19 quality‐adjusted life years at an incremental cost of $16 815/patient. The incremental cost‐effectiveness ratio was $87 725/quality‐adjusted life years gained. Results were consistent across payors, subpopulations, and in deterministic sensitivity analyses. In probabilistic sensitivity analyses, empagliflozin plus standard of care was cost‐effective in 3%, 62%, and 80% of iterations at thresholds of $50 000, $100 000, and $150 000/quality‐adjusted life years. Conclusions: Empagliflozin plus standard of care may prevent hospitalizations for heart failure, extend life, and increase quality‐adjusted life years for patients with heart failure with reduced ejection fraction at an acceptable cost for US payors.
- 31 March 2023
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 21 (3.5) , HSR23-100
HSR23-100: The Potential Clinical Impact of a Multi-Cancer Early Detection Test for Individuals With Missing Cancer Stage Information
"HSR23-100: The Potential Clinical Impact of a Multi-Cancer Early Detection Test for Individuals With Missing Cancer Stage Information" published on 31 Mar 2023 by National Comprehensive Cancer Network.
- 31 March 2023
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 21 (3.5) , HSR23-100
HSR23-100: The Potential Clinical Impact of a Multi-Cancer Early Detection Test for Individuals With Missing Cancer Stage Information
"HSR23-100: The Potential Clinical Impact of a Multi-Cancer Early Detection Test for Individuals With Missing Cancer Stage Information" published on 31 Mar 2023 by National Comprehensive Cancer Network.
- Open Access
- 4 December 2022
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 24 (9) , 1441-1454
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Purpose: This research examined the cost-effectiveness of adding empagliflozin to standard of care (SoC) compared with SoC alone for treatment of heart failure with reduced ejection fraction (HFrEF) from the perspective of healthcare payers in the United Kingdom (UK), Spain and France. Methods: A lifetime Markov cohort model was developed to simulate patients’ progression through health states based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The model predicted risk of death, hospitalisation for worsening heart failure (HHF), treatment-related adverse events, and treatment discontinuation each monthly cycle. Clinical inputs and utilities were derived from EMPEROR-Reduced trial data, supplemented by published literature and national costing databases. Costs (2021 pound sterling/euro) and quality-adjusted life-years (QALYs) were discounted annually for the UK (3.5%), Spain (3.0%) and France (2.5%). Results: In the UK, Spain and France, empagliflozin plus SoC yielded additional QALYs (0.19, 0.23 and 0.21) at higher cost (£1185, €1770 and €1183 per patient) than SoC alone, yielding incremental cost-effectiveness ratios of £6152/QALY, €7736/QALY and €5511/QALY, respectively. Reduced HHF incidence provided most cost offsets for empagliflozin plus SoC. Similar results were obtained for a range of subgroups and sensitivity analyses. Probabilistic sensitivity results indicated empagliflozin plus SoC remained cost-effective vs. SoC at willingness-to-pay thresholds of £20,000/QALY, €20,000/QALY and €30,000/QALY in 79.6%, 75.5% and 97.3% of model runs for the UK, Spain and France, respectively. Conclusions: Empagliflozin added to SoC leads to health benefits for patients with HFrEF and is a cost-effective treatment option for payers in multiple European countries (UK, Spain, France).
- 4 December 2022
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 24 (9) , 1441-1454
Open AccessA European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Purpose: This research examined the cost-effectiveness of adding empagliflozin to standard of care (SoC) compared with SoC alone for treatment of heart failure with reduced ejection fraction (HFrEF) from the perspective of healthcare payers in the United Kingdom (UK), Spain and France. Methods: A lifetime Markov cohort model was developed to simulate patients’ progression through health states based on Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. The model predicted risk of death, hospitalisation for worsening heart failure (HHF), treatment-related adverse events, and treatment discontinuation each monthly cycle. Clinical inputs and utilities were derived from EMPEROR-Reduced trial data, supplemented by published literature and national costing databases. Costs (2021 pound sterling/euro) and quality-adjusted life-years (QALYs) were discounted annually for the UK (3.5%), Spain (3.0%) and France (2.5%). Results: In the UK, Spain and France, empagliflozin plus SoC yielded additional QALYs (0.19, 0.23 and 0.21) at higher cost (£1185, €1770 and €1183 per patient) than SoC alone, yielding incremental cost-effectiveness ratios of £6152/QALY, €7736/QALY and €5511/QALY, respectively. Reduced HHF incidence provided most cost offsets for empagliflozin plus SoC. Similar results were obtained for a range of subgroups and sensitivity analyses. Probabilistic sensitivity results indicated empagliflozin plus SoC remained cost-effective vs. SoC at willingness-to-pay thresholds of £20,000/QALY, €20,000/QALY and €30,000/QALY in 79.6%, 75.5% and 97.3% of model runs for the UK, Spain and France, respectively. Conclusions: Empagliflozin added to SoC leads to health benefits for patients with HFrEF and is a cost-effective treatment option for payers in multiple European countries (UK, Spain, France).